632 related articles for article (PubMed ID: 23451830)
1. Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis.
Huang S; Shao K; Liu Y; Kuang Y; Li J; An S; Guo Y; Ma H; Jiang C
ACS Nano; 2013 Mar; 7(3):2860-71. PubMed ID: 23451830
[TBL] [Abstract][Full Text] [Related]
2. Tumor targeting and microenvironment-responsive nanoparticles for gene delivery.
Huang S; Shao K; Kuang Y; Liu Y; Li J; An S; Guo Y; Ma H; He X; Jiang C
Biomaterials; 2013 Jul; 34(21):5294-302. PubMed ID: 23562171
[TBL] [Abstract][Full Text] [Related]
3. Activatable cell penetrating peptide-conjugated nanoparticles with enhanced permeability for site-specific targeting delivery of anticancer drug.
Xia H; Gu G; Hu Q; Liu Z; Jiang M; Kang T; Miao D; Song Q; Yao L; Tu Y; Chen H; Gao X; Chen J
Bioconjug Chem; 2013 Mar; 24(3):419-30. PubMed ID: 23350619
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth.
Liu XQ; Xiong MH; Shu XT; Tang RZ; Wang J
Mol Pharm; 2012 Oct; 9(10):2863-74. PubMed ID: 22924580
[TBL] [Abstract][Full Text] [Related]
5. Enhancing cancer targeting and anticancer activity by a stimulus-sensitive multifunctional polymer-drug conjugate.
Tu Y; Zhu L
J Control Release; 2015 Aug; 212():94-102. PubMed ID: 26113423
[TBL] [Abstract][Full Text] [Related]
6. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer.
Moura V; Lacerda M; Figueiredo P; Corvo ML; Cruz ME; Soares R; de Lima MC; Simões S; Moreira JN
Breast Cancer Res Treat; 2012 May; 133(1):61-73. PubMed ID: 21805188
[TBL] [Abstract][Full Text] [Related]
7. Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis.
Ding Y; Wang Y; Zhou J; Gu X; Wang W; Liu C; Bao X; Wang C; Li Y; Zhang Q
Biomaterials; 2014 Aug; 35(25):7214-27. PubMed ID: 24875759
[TBL] [Abstract][Full Text] [Related]
8. Platelet-camouflaged nanococktail: Simultaneous inhibition of drug-resistant tumor growth and metastasis via a cancer cells and tumor vasculature dual-targeting strategy.
Jing L; Qu H; Wu D; Zhu C; Yang Y; Jin X; Zheng J; Shi X; Yan X; Wang Y
Theranostics; 2018; 8(10):2683-2695. PubMed ID: 29774068
[TBL] [Abstract][Full Text] [Related]
9. Angiopep-2 and activatable cell-penetrating peptide dual-functionalized nanoparticles for systemic glioma-targeting delivery.
Gao H; Zhang S; Cao S; Yang Z; Pang Z; Jiang X
Mol Pharm; 2014 Aug; 11(8):2755-63. PubMed ID: 24983928
[TBL] [Abstract][Full Text] [Related]
10. Improved therapeutic responses for liposomal doxorubicin targeted via thrombospondin peptidomimetics versus untargeted doxorubicin.
Rivera-Fillat MP; Reig F; Martínez EM; Grau-Oliete MR
J Pept Sci; 2010 Jul; 16(7):315-21. PubMed ID: 20552567
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of targeted multifunctional nanocomplex co-delivery of siRNA and low-dose doxorubicin in breast cancer.
Dong D; Gao W; Liu Y; Qi XR
Cancer Lett; 2015 Apr; 359(2):178-86. PubMed ID: 25592040
[TBL] [Abstract][Full Text] [Related]
12. Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO
Zhu R; Wang Z; Liang P; He X; Zhuang X; Huang R; Wang M; Wang Q; Qian Y; Wang S
Acta Biomater; 2017 Nov; 63():163-180. PubMed ID: 28923539
[TBL] [Abstract][Full Text] [Related]
13. Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system.
Chen B; Dai W; Mei D; Liu T; Li S; He B; He B; Yuan L; Zhang H; Wang X; Zhang Q
J Control Release; 2016 Nov; 241():68-80. PubMed ID: 27641831
[TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
15. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
[TBL] [Abstract][Full Text] [Related]
16. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.
Dickson PV; Hamner JB; Sims TL; Fraga CH; Ng CY; Rajasekeran S; Hagedorn NL; McCarville MB; Stewart CF; Davidoff AM
Clin Cancer Res; 2007 Jul; 13(13):3942-50. PubMed ID: 17606728
[TBL] [Abstract][Full Text] [Related]
18. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
19. Tumor microenvironment-specific nanoparticles activatable by stepwise transformation.
Ko H; Son S; Jeon J; Thambi T; Kwon S; Chae YS; Kang YM; Park JH
J Control Release; 2016 Jul; 234():68-78. PubMed ID: 27164544
[TBL] [Abstract][Full Text] [Related]
20. Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor.
Li X; Wu M; Pan L; Shi J
Int J Nanomedicine; 2016; 11():93-105. PubMed ID: 26766908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
